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N =# of states whose data was used in analysis; corco=correlation coeffecient.
Conclusion: In a national sample of community dwelling elderly, self-reported health-
related variables were significantly associated with hospital admission rates for CVD. 
These variables included factors related to life style, prevention, access, and health sta-
tus. While our findings should be viewed as hypothesis generating, they provide insight 
into risk factors for CVD in the elderly, and support the promotion of healthy lifestyle 
behaviors and the improvement of access to care as potentially effective mechanisms for 
the prevention and control of cardiovascular disease in this population.
1128-129 The Incidence and Prognostic Value of Exertional 
Hypotension in Medically Managed Older Patients With 
Stable Coronary Artery Disease
Giridhar Logsetty, Yinong Young-Xu, Charles M. Blatt, Shmuel Ravid, Lown 
Cardiovascular Research Foundation, Brookline, MA, Brigham & Women's Hospital, 
Boston, MA
Background: The elderly are the fastest growing segment of patients with coronary
artery disease (CAD). Since optimal management of CAD requires several drugs that
lower blood pressure, we studied the incidence and prognostic value of exertional
hypotension (EH) in older patients with stable CAD.
Methods: 564 patients (mean age 67) were studied prospectively. EH was defined as a
drop in blood pressure below the resting value. Occurrence of death and/or non-fatal
myocardial infarction (MI) was the primary endpoint.
Results: 90 patients (16%), mean age 69, experienced EH. Older age (HR 1.3, 95% CI
1.02 -1.65, p = 0.03), and the use of multiple vasoactive drugs (HR 1.4, 95% CI 1.1 - 1.8,
p =0.006) were predictive of EH. In univariate but not in multivariate analysis, EH was
associated with a higher risk for the primary endpoint (HR 1.67, 95% CI 1.01- 2.77, p <
0.05). Beta-blocker use (HR 0.47, 95% CI 0.26 – 0.85, p = 0.01), and longer treadmill
time (HR 0.40, 95% CI 0.25 – 0.64, p < 0.001) were associated with improved outcomes.
EH occurring with ischemia was strongly associated with the primary endpoint (4.8% ver-
sus 1.6%, p=0.04, % annually). EH without ischemia posed no additional risk (1.6% ver-
sus 1.2%, p = 0.41, % annually). Finally, EH developing after stage 2 of the Bruce
protocol was not associated with worse outcomes.
Conclusions: EH is common in older patients with stable CAD managed with multiple
medications and is not strongly predictive of worse outcomes in the absence of ischemia
and/or impaired exercise tolerance.
1128-130 The Blood Pressure Response to the Valsalva 
Maneuver: An Independent Predictor of Mortality in 
Elderly Cardiac Patients
Jaap J. Remmen, Wim R. Aengevaeren, Marc A. Brouwer, Freek W. Verheugt, Rene W. 
Jansen, University Medical Center, Nijmegen, The Netherlands
Introduction: The number of elderly cardiac patients is increasing. The prognosis of
these patients is poor. Yet, it is difficult to estimate the prognosis for an individual patient.
The blood pressure (BP) response to the Valsalva maneuver (VM) is related to cardiac
filling pressure and may be used to estimate prognosis. We studied if the BP response to
the VM was associated with mortality in elderly patients with various cardiac disorders.
Methods: In 93 patients, aged 71±5 yr (mean±SD) undergoing right-sided catheteriza-
tion, the VM was performed. Continuous BP was measured non-invasively with Finapres.
From the BP response to the VM, the Pulse Pressure Ratio (PPR) was calculated as the
ratio of lowest and highest PP. Survival was assessed from medical files or by telephone.
Kaplan Meier survival was calculated for PPR tertiles and Cox regression for the prog-
nostic value of PPR together with established prognostic variables.
Results: Follow-up period was 28 months. Survival differed significantly over the tertiles
(Figure). PPR was an independent predictor of death; Hazard Ratio: 1.56 (per step of
0.1); 95%CI: 1.14 - 2.12, P=0.006), in a model with age, gender, LVEF, HF admittance,
myocardial infarction, heart rate, presence of pulmonary rales, NYHA class.
Conclusion: In this group of elderly cardiac patients, the PPR of the Valsalva maneuver
was an independent non-invasive prognostic marker for mortality. Prospective studies on
the predictive value of the BP response to the Valsalva maneuver are warranted. 
1128-131 Do Elderly Patients With Acute Myocardial Infarction 
Show the "Smoker´s Paradox"? Results From the 
PPRIMM75 Registry
Hector Bueno, Hugo D. Juan, Manuel Martinez-Selles, Esther Perez-David, Hospital 
General Universitario "Gregorio Maranon", Madrid, Spain
Background. Although smokers (S) are at an increased risk of myocardial infarction (MI),
the outcome of MI is better in S than in non-S. The reason for this paradox is uncertain
but it has been attributed, at least in part, to the younger age of S.
Methods. To assess if the smoker’s paradox is present in a population of advanced age,
we studied baseline characteristics and outcomes in 677 consecutive patients enrolled in
the PPRIMM75 Registry from 1988 to 1997 (aged >75 years and admitted to our CCU
with a first AMI).
Results: S were younger (79 vs 80.7 years)*, and less frequently female (5.4 vs 63%)*,
diabetic (26 vs 34%, p=.06) and hypertensive (32 vs 57%)*, but had more often periph-
eral artery disease (24 vs 11%)*. S arrived earlier (delay <6h: 30 vs 38%, p=.08) and
were more frequently in Killip class I (77 vs 63%)*. They presented similar rates of ST-
segment elevation (84%) and of anterior MIs (34%). No differences between S and non-S
were found in the use of reperfusion therapy, echocardiography and coronary angiogra-
phy. Stress tests were more frequently used in S (34 vs 13%)*. LVEF was similar in both
groups. During hospitalization, S showed a lower incidence of pulmonary congestion (32
vs 44%, p<.02), cardiogenic shock (14 vs 19%, p=.13), mechanical complications (6 vs
10%, p=.16). In-hospital mortality rate was 22% in S and 33% in non-S (p=.012). After
adjusting the difference in age by logistic regression analysis smoking remained as an
independent predictor of death (OR: 0.62; 95%CI: 0.39-0.99). However, when the other
baseline differences and Killip class were taken into account, smoking lost its “protective”
effect (OR: 0.85; 95% CI: 0.49-1.47). After a mean follow-up of 51 months, S showed a
slight advantage in survival (p=.091). When baseline characteristics and Killip class were
included in a Cox regression model, S did not show any difference in long-term outcome
(OR: 1.08, 95%CI: 0.82 - 1.42). * p<0.01
Conclusion. The smoker’s paradox can also be observed in elderly patients with AMI.
However, most of the short-term mortality advantage is offset when baseline characteris-
tics are controlled. There is no long-term survival benefit associated with smoking in
older patients.
1128-132 Influence of Age on Atrial Fibrillation Induction
Beatrice Brembilla-Perrot, Guillaume Burger, Olivier Claudon, Daniel Beurrier, Pierre 
Houriez, Arnaud Terrier de la Chaise, Pierre Louis, Marius Andronache, Emad Khaldi, 
CHU of Brabois, Vandoeuvre Les Nancy, France
Background : atrial fibrillation (AF) induction is used as a diagnostic test of atrial vulnera-
bility in adults; some electrophysiologic changes were reported during the life; AF preva-
lence is known to increase in elderly people; however, the effects of age on AF induction
are unknown. The purpose of the study was to evaluate the effects of age on atrial fibril-
lation induction. Methods : population of study consisted of 757 patients without sponta-
neous AF, aged from 16 to 85 years (y) (mean 61±15), admitted for an electrophysiologic
study, indicated for dizziness or ventricular tachyarrhythmia. Programmed atrial stimula-
tion was systematically performed : 1 and 2 extrastimuli were delivered in sinus rhythm
and 2 atrial driven rhythms (600, 400 ms). AF induction was defined as the induction of
AF lasting more than 1 minute. Clinical and electrophysiological data were statistically
analysed.
Results : AF induction was paradoxically decreased in the elderly patients ( >70 y) com-
pared to patients younger than 70 y (p <0.01) : AF was induced in 40 % of 64 patients
younger than 40 y, 39 % of 103 patients aged 40 to 50 y, 37 % of 131 patients aged 50 to
60 y, 38 % of 224 patients aged 60 to 70 y and only 28 % of 235 patients older than 70 y.
There was no significant correlation with the sex, the presence of dizziness, the presence
of an underlying heart disease, the left ventricular ejection fraction, the presence of sal-
vos of atrial premature beats on Holter monitoring and the intra-atrial conduction time.
There was a significant correlation with a longer effective atrial refractory period in the
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Predictors of MI and/or Death
Predictors of EH Hazard Ratio 95% C.I. p value
Age 1.30 1.02 - 1.65 0.03*
# of Drugs 1.39 1.10 - 1.75 0.006*
Predictors of Non-fatal MI or Death Hazard Ratio 95% C.I. p value
EH 1.52 0.88 - 2.66 0.14
Beta-blocker use 0.47 0.26 - 0.85 0.01*
Treadmill Time (> 6 min) 0.40 0.25 - 0.64 < 0.001*
History of hypertension 1.33 0.80 - 2.21 0.27
Left Ventricular Function 0.88 0.73 - 1.07 0.20
# of Drugs 1.42 1.05 - 1.92 0.03*
Ventricular Arrhythmia during Exercise testing 0.85 0.12 -6.31 0.88
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elderly (225±41 ms) than in younger patients (208±31 msec) (p<0.001). Increased atrial
refractory period and age > 70 years were independent factors of decreased AF inducibil-
ity. Conclusion : AF inducibility is paradoxically decreased in elderly patients. The AF
induction is facilitated by the presence of a short atrial refractory period in patients
younger than 70 years and programmed atrial stimulation should be interpreted cau-
tiously in these patients. In the opposite, the increase of atrial refractory period could pro-
tect the patients older than 70 years against AF induction.
ORAL CONTRIBUTIONS
839 Hypertrophic Cardiomyopathy: Basic and 
Clinical II
Tuesday, March 09, 2004, 10:30 a.m.-Noon
Morial Convention Center, Room 210
10:30 a.m.
839-1 The Long-Term Effect of Surgical Myectomy on Survival 
in Patients With Obstructive Hypertrophic 
Cardiomyopathy
Steve R. Ommen, Iacopo Olivotto, Martin S. Maron, Sandro Betocchi, Franco Cecchi, 
Michael J. Ackerman, Bernard J. Gersh, Joseph A. Dearani, Hartzell V. Schaff, Rick A. 
Nishimura, Barry J. Maron, Mayo Clinic, Rochester, MN
Background: Surgical septal myectomy is the definitive treatment for relief of drug-refrac-
tory symptoms in hypertrophic cardiomyopathy (HCM). Recent data document reduced
survival when left ventricular outflow (LVOT) obstruction is present. However, the poten-
tial effects of myectomy on long-term survival are unresolved.
Methods: Overall mortality was assessed in 1337 HCM pts evaluated between 1983-
2001: (1) 289 consecutive pts underwent isolated surgical myectomy at Mayo Clinic for
advanced symptoms attributable to LVOT obstruction; (2) 228 other pts with LVOT
obstruction were managed without surgery; (3) 820 pts had nonobstructive HCM. Sur-
vival after myectomy was compared to age and sex matched general population, nonop-
erated obstructive pts, and nonobstructive pts.
Results: Patients were 45 ± 20 years old, 58% were males, LV wall thickness was 22 ± 6
mm, the average resting gradient was 68 ± 37mmHg among the pts with LVOT obstruc-
tion. Including 4 operative deaths (procedural mortality, 1.4%), survival after myectomy at
1, 5, and 10 years was 98%, 96%, and 83%, respectively. This survival did not differ sta-
tistically from the age and sex matched general population, nor the pts with nonobstruc-
tive HCM (98%, 95%, 88%). Myectomy pts had more favorable survival than nonoperated
obstructive pts (90%, 80%, and 67%, log-rank p <0.0001). Multivariate Cox modelling
with all relevant co-variates showed that myectomy (hazard ratio 0.20, p<0.0001) was
independently associated with more favorable long-term survival.
Conclusion: Surgical septal myectomy performed for the relief of LVOT obstruction and
severe drug-refractory symptoms is associated with long-term survival equivalent to that
of an age and sex matched general population. Although these data are retrospective
and nonrandomized, they strongly suggest that myectomy reduces the excess mortality
risk associated with the presence of LVOT obstruction.
10:45 a.m.
839-2 Mechanism of Systolic Anterior Motion and 
Regurgitation Post Septal Ablation in Hypertrophic 
Cardiomyopathy
Francesca Nesta, Danita M. Yoerger, Michael H. Picard, Michael A. Fifer, Igor F. Palacios, 
Gus J. Vlahakes, Robert A. Levine, Judy Hung, Massachusetts General Hospital, 
Boston, MA
Background: Systolic anterior motion of the mitral valve (SAM) in hypertrophic cardi-
omyopathy (HCM) is secondary to both outflow tract narrowing and primary structural
abnormalities of the mitral apparatus: the papillary muscles (PM) and leaflets are shifted
anteriorly into the LV outflow path, causing SAM with regurgitation (MR). Clinical obser-
vations suggest that relief of obstruction by septal ablation (SAb) does not always cause
resolution of SAM and MR. We tested the hypothesis that persistent SAM relates to mal-
position of the mitral apparatus, and that this finding can predict persistence of SAM.
Methods: We reviewed echoes of 30 patients with HCM before and 3 months post SAb.
We assessed anterior leaflet malposition by the antero-posterior projection of the coapta-
tion point onto the mitral annular diameter (A/D ratio) in early systole. MR was assessed
by proximal jet in the LAX view. Results: Most patients (22/30=73%) had SAM at 3
months despite successful SAb (gradient reduction > 50%), and had more anterior mal-
position and less MR reduction than those without SAM: A/D 0.44 vs 0.57, MR proximal
jet reduction by 7% vs 51%, p < 0.0001. Anterior malposition was also present prior to
SAb, with A/D < 0.4 being predictive of SAM post SAb (p<0.007). Conclusions: SAM
and its related MR are not always eliminated by SAb. MV malposition is a strong determi-
nant and predictor of SAM and MR reduction post SAb and may represent a new thera-
peutic target during ablation procedures. 
11:00 a.m.
839-3 Frequency, Spectrum, and Phenotype of Hypertrophic 
Cardiomyopathy Patients With Multiple Sarcomeric 
Mutations
Sara L. Van Driest, Steve R. Ommen, Melissa L. Will, Vlad C. Vasile, Susan Chung, A. 
Jamil Tajik, Bernard J. Gersh, Michael J. Ackerman, Mayo Clinic, Rochester, MN
Background: Hypertrophic cardiomyopathy (HCM) is caused by pathogenic mutations
involving 8 genes that encode critical proteins comprising the sarcomere. Here, we deter-
mine the frequency, spectrum, and phenotype associated with complex genetic status
(i.e. > 1 sarcomeric mutation) in a cohort of unrelated patients (pts) evaluated at a tertiary
outpatient HCM clinic.
Methods: DNA was obtained from 389 unrelated HCM pts and analyzed for mutations in
myosin binding protein C encoded by MYBPC3, β -myosin heavy chain (MYH7), regula-
tory and essential light chains (MYL2 and MYL3), troponin T (TNNT2), troponin I
(TNNI3), α -tropomyosin (TPM1), and actin (ACTC) using polymerase chain reaction,
denaturing high performance liquid chromatography, and DNA sequencing. Clinical data
were extracted from pt records blinded to pt genotype.
Results: Of the 389 HCM pts, 151 (38.8%) harbored at least one putative pathogenic
mutation. Eleven pts (2.8% of total and 7.2% of genotyped subset) had 2 putative sarco-
meric mutations: compound MYBPC3 in 2 pts, MYBPC3 and MYH7 (3), MYBPC3 and
TNNT2 (2), MYBPC3 and TNNI3 (1), MYBPC3 and TPM1 (1), compound MYH7 (1), and
MYH7 and TNNT2 (1). When compared to pts with single sarcomeric mutations, or no
sarcomeric mutations, pts with multiple mutations were younger at diagnosis (21.7 ± 11
years vs 36.4 ± 17 vs 45.1 ± 19, p <0.005, had greater hypertrophy (maximum left ven-
tricular wall thickness = 24.6 ± 12 mm vs 22.8 ± 6 vs 20.7 ± 6, p <0.05), and more fre-
quently received an ICD (36% vs 24% vs 10%, p = 0.0002). However, those with multiple
mutations were not more likely to have had a surgical myectomy than those with a single
mutation or no identifiable sarcomeric mutation.
Conclusion: This study represents a comprehensive mutational analysis searching for
multiple genetic defects in a large HCM cohort from a single tertiary referral center. Com-
plex genetic status was found in nearly 3% of HCM pts. On average, pts with multiple sar-
comeric mutations were diagnosed 20 years earlier and displayed the greatest degree of
hypertrophy. The possibility of multiple mutations involving the sarcomere adds further
complexity to the development and implementation of clinical molecular genetic testing
for HCM.
11:15 a.m.
839-4 Treatment With Antioxidant N-Acetylcysteine Reverses 
Interstitial Fibrosis in a Mouse Model of Human 
Hypertrophic Cardiomyopathy Mutation
Natalia Tsybouleva, Tripti Halder, Rajnikant Patel, Silvia Lutucuta, Gilberto De Freitas, 
Masakuni Ishiyama, Blase Carabello, Ali J. Marian, Baylor College of Medicine, Houston, 
TX
The genetic basis of human hypertrophic cardiomyopathy (HCM) is known but the patho-
genesis of its phenotypes is unknown. We have generated transgenic mice by cardiac-
restricted expressing mutant cardiac troponin T (cTnT)-Q92 protein, known to cause
HCM in humans; which exhibits enhanced systolic function, interstitial fibrosis (IF) and
myocyte disarray. Since oxidative stress is implicated in the pathogenesis of fibrosis, we
tested whether treatment with anti-oxidant N-acetyl cysteine (NAC) could reverse or
attenuate IF in the cTnT-Q92 mice. We performed a placebo-controlled study and ran-
domized 24 mice to placebo or NAC (1g/Kg/d) and include 12 non-transgenic (NTG) mice
as controls. We performed echocardiography prior to and after 16 weeks of therapy fol-
lowed by histological and molecular characterization. Transgenic mice had higher left
ventricular (LV) ejection fraction and smaller LV end systolic diameter and smaller heart
weight/body weight (HW/BW) as compared to NTG mice at the baseline. No significant
differences in the body weight, male/female ratio, mean age, and heart rates were
present among the three groups. Treatment with NAC reduced concentrations of alondi-
aldehyde and 4-hydroxy-2(E)-nonenal, indices of oxidative stress, in the left ventricular
tissue (NTG: 3.0 ± 0.6; Placebo: 3.5 ± 0.4; NAC: 2.3 ± 0.3, p=0.01). Similarly, collagen
volume fraction (CVF) was normalized (NTG: 3.4% ± 0.9; Placebo: 7.8 ± 1.7; NAC: 3.8 ±
